Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$282000.0.

  • Enanta Pharmaceuticals' Non Operating Income fell 14221.56% to -$282000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 5388.16%. This contributed to the annual value of $1.8 million for FY2025, which is 5388.16% down from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Non Operating Income stood at -$282000.0, which was down 14221.56% from $667000.0 recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Non Operating Income peaked at $1.9 million during Q2 2023, and registered a low of -$282000.0 during Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' median Non Operating Income value was $668000.0 (recorded in 2024), while the average stood at $781684.2.
  • Its Non Operating Income has fluctuated over the past 5 years, first soared by 62039.22% in 2023, then crashed by 14221.56% in 2025.
  • Enanta Pharmaceuticals' Non Operating Income (Quarter) stood at $258000.0 in 2021, then skyrocketed by 284.88% to $993000.0 in 2022, then dropped by 13.7% to $857000.0 in 2023, then dropped by 2.33% to $837000.0 in 2024, then crashed by 133.69% to -$282000.0 in 2025.
  • Its Non Operating Income was -$282000.0 in Q3 2025, compared to $667000.0 in Q2 2025 and $578000.0 in Q1 2025.